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Background: Diet is known to play a major role in irritable bowel syndrome (IBS) with 
many people identifying certain foods as a trigger for symptoms. Recently, reducing 
fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) 
has been shown to help alleviate symptoms in IBS patients. The mechanisms through 
which FODMAPs trigger symptoms have been well established, yet there are limited 
studies investigating the relationship between FODMAP content in the diet and IBS 
symptoms. Although, patients have reported symptom onset in the following few hours 
after a meal, there has been limited research surrounding acute symptom onset and its 
relationship with FODMAP intake. 
Objective: The aims of this study are to investigate the relationship between dietary 
FODMAP intake and acute gastrointestinal symptoms in IBS adults and the effect of 
individual FODMAPs on these acute gastrointestinal symptoms.  
Design: 
Data were collected from 103 participants from two IBS cohorts; the Christchurch IBS 
COhort to investigate Mechanisms For Gut Relief and Improved Transit (COMFORT) 
 study and the Food And Symptom Times (FAST) validation study. Relevant data 
collected included demographic forms, diagnostic questionnaires and food and 
symptom data. Participants completed a three-day food and symptom diary over three 
non-consecutive days. Symptoms assessed included abdominal pain, abdominal 
bloating, abdominal swelling, abdominal distension and bowel motions which were 
recorded on a 24-hour scale stating the time, duration and severity. All food items and 
beverages from the food diaries were entered in a FODMAP analysis software to 
analyze the FODMAP content of each meal. Symptom data were recorded into an excel 
sheet. ANOVA tests and receiver operating characteristic (ROC) curves were used to 
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investigate the relationship between FODMAP intake and acute gastrointestinal 
symptoms and the effects of individual FODMAPs on these symptoms. 
Results: The presence of abdominal pain and bowel motions following a meal were 
associated with a significantly higher intake compared to those not experiencing 
symptoms for both FODMAPs (3.98g v 3.24g and 4.27g v 3.12g, p<0.05), and for 
fructans (0.77g v 0.48g and 0.76g v 0.47g, p<0.05). Overall there were no significant 
correlations between increasing FODMAP intake and the proportion of people 
experiencing abdominal symptoms. A significant correlation was found between 
increasing FODMAP intake and the proportion of people with acute bowel motions 
following a meal. Oligosaccharides (GOS and fructans) had significant correlations 
between increasing intake and the percentage of patients experiencing abdominal pain, 
abdominal, fullness and bowel motions (p<0.05). There was no significant difference 
between average FODMAP intake and the severity of acute symptoms reported. A 
significantly higher intake of lactose was associated with lower severity of fullness and 
swelling compared to those reporting higher severity and a higher excess fructose intake 
was associated with a higher severity of abdominal swelling. 
Conclusion: 
 
These findings support the role of FODMAPS in acute symptom onset however, the 
amount and type of FODMAPs triggering symptoms varies between individuals for 
most FODMAPs. This study highlights the importance of individualized dietary advice 





The FAST validation study is a prospective observational pilot study of 51 IBS 
participants based in Christchurch and Dunedin. The aim of this study was to validate a 
time-specific food and symptom diary, that if successful would be used in the 
COMFORT cohort. The other aim was to investigate the consumption of foods 
including fibre, gluten and FODMAPs (low, medium and high intake) and subsequent 
gastrointestinal symptoms. Recruitment began in September 2016 till April 2017.  This 
thesis uses data from all 51 participants in the FAST validation study. 
As a continuation of the FAST validation study, this thesis will focus on the effect of 
FODMAPs on subsequent symptoms, but rather than looking at FODMAPs by low, 
medium or high categories like the FAST validation study, the effects of specific 
amounts of FODMAPs on subsequent gastrointestinal symptoms will be investigated.  
 
Data used in this thesis were also collected from the COMFORT study. The 
COMFORT study is a prospective case-control study of approximately 600 patients 
with or without IBS undergoing a colonoscopy in Christchurch. Recruitment began in 
March 2016 and is still ongoing (May 2018). The aim of this study is to investigate the 
mechanisms involved in IBS pathogenesis.  The first 52 participants in the COMFORT 
study with IBS who had completed and returned their three-day food and symptom 
diary (FAST) were included in this thesis.  
 
The aim of this thesis is to investigate the relationship between dietary FODMAP intake 
and acute symptoms. The relationship between individual FODMAPs and acute 




As part of this thesis, the candidate: 
- Reviewed the data of participants relevant to this thesis and checked data for 
completion.  
- Completed data entry for 103 participants’ three-day food and symptom diaries 
into the Monash FODMAP calculator. 
- Was responsible for choosing suitable FODMAP substitutions to food items 
missing on the FODMAP analysis software. 
- Largely undertook the statistical analyses presented in this thesis with advice 
and guidance from the statistician for the statistical testing. 
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Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with a 
global prevalence of 11.2% varying greatly between countries (1). IBS is characterized 
by abdominal pain and is associated with a change in bowel habits. A diagnosis of IBS 
is made using symptom-based criteria, the Rome IV criteria are most commonly used in 
practice (2).  
 
Diet is known to be a trigger for IBS symptoms with many people attributing certain 
foods to the worsening of symptoms (3, 4). Many dietary therapies have been studied 
and used in the community to help alleviate symptoms with varying levels of supporting 
evidence. The UK NICE guidelines were traditionally used for first line management in 
NZ and include eliminating common trigger foods such as spicy foods, fatty foods, 
alcohol and caffeine, and focusing on eating behaviours and physical activity (5, 6). 
More recently, reducing a group of fermentable short-chain carbohydrates (known as 
FODMAPs) have been shown to be effective at improving IBS symptoms and the low 
FODMAP diet is now commonly used in practice for the management of IBS (7-9).  
 
The mechanisms behind which FODMAPs induce IBS symptoms have been well 
researched. FODMAPs are poorly absorbed in all individuals leading to colonic 
fermentation producing gas whilst their osmotic nature draws water into the bowel (10). 
The gas produced by fermentation and the increase in water delivery due to the osmotic 
properties of FODMAPS have been shown to cause luminal distension (11-13). In 
patients with IBS, this luminal distension has been shown to cause symptoms of 




Poor absorption of FODMAPs occurs, to some degree, in all individuals. The reason 
that these mechanisms trigger symptoms in IBS patients only is not clearly understood 
but is thought to be related to factors such as visceral afferent hypersensitivity, altered 
gut microbiota and disordered gut motility that are less common in healthy people (10, 
14). 
 
The relationship between FODMAP consumption and symptom onset in IBS patients 
has been shown in a few studies using liquid formulations of FODMAPs (15-18). 
However, evidence on the specific amount of FODMAPs causing these symptoms is 
limited and most studies have used liquid formulations of FODMAPs rather assessing 
the FODMAP content in the diet. 
 
Although many patients have reported symptoms in the following few hours after a 
meal (3), the relationship between FODMAP intake and the onset of acute symptoms 
has not been well investigated. Previous research has suggested that it is not the amount 
of individual FODMAPs consumed at meal that is a predictor for the onset of 
symptoms, but rather the overall FODMAP content of a meal (10). However, no studies 
have assessed the relationship between dietary FODMAP content and the onset of acute 
gastrointestinal symptoms in IBS patients or the effect of individual FODMAPs on 
these symptoms.  
 
The aim of this study is to investigate the relationship between dietary FODMAP intake 
and acute gastrointestinal symptoms in adults with IBS and investigate the role 





2. Literature Review 
The relevant literature used in this review were identified by searching the databases; 
WEB OF SCIENCE, SCOPUS and PUBMED. The key terms used were; ‘irritable 
bowel syndrome’, ‘diagnosis’, ‘prevalence’, ‘FODMAPs’, ‘gastrointestinal symptoms’, 
‘symptom onset’, ‘low FODMAP diet’ and ‘dietary intervention’. All searches were for 
English full-text articles only. References from articles found in these databases were 
also reviewed for relevant articles. 
2.1 Irritable Bowel Syndrome 
Irritable bowel syndrome (IBS) is a functional bowel disorder characterised by 
abdominal pain and a change in bowel habit (19). Patients with IBS can be classified 
into one of four subtypes depending on the predominant stool form they have: IBS-D 
(diarrhoea predominant), IBS-C (constipation predominant), IBS-M (mixed) and IBS-U 
(un subtyped) (20). These subtypes, defined by Rome IV, are to help with the 
management of symptoms and treatment (21).  
IBS can reduce quality of life, impact work productivity, and is associated with 
increased health care costs (19). It has been estimated that patients with IBS are willing 
to sacrifice up to 15 years of their life to be cured of this disorder (22). Although, there 
is no cure for IBS, there are many different therapies being used that can help with the 
management of symptoms. 
2.1.1 Diagnosis 
Traditionally IBS was a diagnosis made by exclusion. This involved many invasive and 
expensive tests including laboratory tests, colonoscopy with random biopsies, upper 
duodenal biopsies, hydrogen breath tests and CT scans (23). Symptom-based criteria 
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were developed to make IBS a positive diagnosis and avoid the unnecessary testing that 
was previously done to rule out organic disease.  
The first symptom-based criteria used for the diagnosis of IBS were the Manning 
criteria in 1978, though, the Rome criteria which evolved from Manning are currently 
recommended for use in practice (24). The Rome criteria were first published in 1992 
and have since been revised many times (25). The most recent criteria, Rome IV were 
published in 2016 and are the first diagnostic criteria to differentiate between subtypes 
making it more useful clinically for the management of IBS (Figure 1).  
Figure 1: Rome IV diagnostic criteria for irritable bowel syndrome (2) 
A positive diagnosis of IBS can be made when a patient fulfils these criteria and after 
limited laboratory testing to rule out other diagnoses. Alarm features that also need to be 
considered as exclusion criteria include: unintentional/unexplained weight loss, 
symptom onset after age 50 years, nocturnal symptoms, rectal bleeding, family history 
of colorectal cancer, inflammatory bowel disease or coeliac disease and iron deficiency 
anaemia (2, 25). Patients that meet the diagnostic criteria for IBS should undergo 
limited tests including; complete blood count, erythrocyte sedimentation rate and in 
patients with diarrhoea; serologic testing for coeliac disease, C-reactive protein and 
faecal calprotectin (26).  
2.1.2 Prevalence of IBS 
The prevalence of IBS differs depending on the type of diagnostic criteria used and 
geographic location. The pooled prevalence globally is 11.2%, varying from 1.1% to 
Recurrent abdominal pain on average at least 1 day/week in the last 3 months, associated with 
two or more of the following criteria: 
1. Related to defecation 
2. Associated with a change in the frequency of stool 
3. Associated with a change in the form (appearance) of stool 
 




45% between countries (1). IBS tends to be more prevalent in women than men (27, 
28), and more prevalent in those under 50 years (29, 30).  
Recent data on the prevalence of IBS in New Zealand are lacking. However, data from a 
New Zealand birth cohort published in 2002 found that 18.8% of young adults in 
Dunedin had IBS using the Manning criteria (28).  
2.1.3 Pathogenesis of IBS 
The exact cause of IBS is unclear, but there has been considerable research into the 
underlying mechanisms of this disorder. Recent research has shown that multiple 
factors could play a role in the pathogenesis of IBS (2). These factors include visceral 
afferent hypersensitivity, abnormal gut motility, low grade intestinal inflammation, 
altered gut-brain axis, genetics and dysbiosis of the intestinal microbiota (6, 26).  
2.2 Therapies for IBS 
IBS is not curable, therefore the goal of treatment is to manage symptoms, especially 
the predominant one in a given individual. There have been many therapies studied for 
the management of IBS symptoms including pharmacological therapies, psychological 
treatments and dietary therapies.   
Traditional pharmacological treatments such as peppermint oil, bulking agents, 
antispasmodics and antidiarrheal agents are used to treat symptoms such as diarrhoea or 
constipation and have been found to be effective (31, 32). However, most 
pharmacological treatments, have an effect on only one symptom (32), and with the 
varied symptoms many with IBS have, these treatments are often not effective for 
global symptom improvement in everyone if used alone (33).  
Probiotics are one of the most extensively studied treatments for the management of 
IBS (34). Probiotics are live bacteria that, when consumed in adequate amounts, display 
6 
 
a benefit to their host (35). It is thought that probiotics may help alter the gut microbiota 
to improve symptoms (35). There are various probiotics available and they can come as 
single or multi strain products and are available in many different forms such as 
capsules, fermented dairy products and powders. Research has shown a beneficial effect 
of probiotics in improving global symptoms in IBS (35). However, there is no 
consistency in either the strain type or dose and, although probiotics appear to help 
symptoms improve, there is not enough evidence to make a recommendation on a 
specific dose and strain (34).  
A therapy that has increasing evidence of efficacy in the management of IBS is gut-
directed hypnotherapy. Many studies have found a significant improvement in 
gastrointestinal symptoms following gut-directed hypnotherapy (36-41).  The response 
rate from hypnotherapy has ranged from 24% to 73% in people with IBS (42). A recent 
randomised controlled trial that compared gut-directed hypnotherapy to the low 
FODMAP diet found similar improvement in both groups suggesting that gut-directed 
hypnotherapy may have similar efficacy to the low FODMAP diet which is currently 
used for the management for IBS (43). 
2.2.1 Dietary therapies 
Diet is known to play a major role in IBS with 63-90% of patients reporting food as a 
trigger of their symptoms (3, 4). There has been a great deal of research into what foods 
may trigger symptoms and how IBS can be managed through diet.  
Foods or food components that patients commonly perceive to trigger symptoms 
include fatty foods, spicy foods, alcohol, caffeine and carbohydrate rich foods. (34). The 
proposed mechanisms behind these are detailed in Table 2.1.  
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Table 2.1: Common Trigger Foods and their Mechanism of Action 
 
Trigger Food Mechanism for symptoms 
Fatty Foods Fat intake has been shown to alter gut motility 
leading to gas accumulation, luminal 
distension and bloating in IBS patients (44).  
Spicy Foods Capsaicin, a component found in red chilli 
may be associated with the symptoms often 
reported in patients with IBS after ingestion of 
spicy foods (45). Capsaicin can accelerate gut 
motility and cause a burning sensation which 
may explain the cause of symptoms in people 
with IBS especially those with visceral 
hypersensitivity (46) 
Alcohol Alcohol has been shown to have an effect on 
gastrointestinal tract motility and absorption, 
and this may lead to diarrhoea in patients with 
IBS (47) 
Caffeine Caffeine is known to increase colon motor 
activity, gastric acid secretion and produce a 
laxative effect in individuals (48). Those with 
IBS may see the effects of caffeine more, 
although there is not strong evidence to 
support this (48). 
Carbohydrate-rich foods Some carbohydrates are osmotic, poorly 
absorbed and later fermented and this is 
thought to cause symptoms in patients with 




The NICE guidelines are often used as the first line approach for patients with IBS. 
These guidelines give general dietary advice to limit/exclude the trigger foods, as well 
as life style advice such as regular exercise, sitting down to eat, having regular meals 
and chewing well (5). These guidelines are based on available evidence or guided by 
clinical experience and opinion. Research has shown some symptomatic improvement 
in patients following use of these guidelines (49-51).    
  
Fibre supplementation has also been well studied as a treatment for IBS symptoms. 
Fibre can improve gastrointestinal transit by increasing the stool bulk with insoluble 
fibre along with increased motility and secretion, or by normalising the stool with 
soluble fibre by its gelatinising effect (52). A systematic review and meta-analysis 
found that fibre supplementation is an effective approach to improve global IBS 
symptoms but, the beneficial effect of fibre is limited to soluble fibre (such as psyllium) 
(53). Insoluble fibre (such as bran) has shown no beneficial effect (53) and has even 
worsened symptoms in IBS patients (34, 54). 
As different types of fibres have different physiological effects, a general 
recommendation of fibre supplementation for IBS patients would not be appropriate. 
There is no evidence to suggest that patients with IBS require more fibre than healthy 
individuals (34) and therefore, an individual’s current fibre intake and subtype should 
be taken into account when recommending fibre supplementation. Many exclusion diets 
have also been used for the management of IBS and details of these diets along with the 
proposed mechanism of action in the management of IBS are listed in Table 2.2. 
As wheat, barley and rye may be associated with symptoms in IBS, the role of gluten 
and whether a gluten free (GF) diet may help in the management of IBS has been 
studied. Two double-blind placebo-controlled randomised controlled re-challenge trials 
have investigated the role of gluten in the genesis of IBS symptoms, and found that 
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symptoms significantly worsened in those receiving gluten compared to placebo (55, 
56).  
The mechanism by which gluten could be having an effect has not been identified and 
the researchers could not isolate the effects of gluten specifically as there may be 
components in the foods/capsules such as fructans that could be playing a role. 
Interestingly, a follow up study by Biesiekierski et al. (2013) found no specific effect of 
gluten on symptoms after patients were on a low FODMAP diet for two weeks (57). 
These studies suggest further evidence of the effects of gluten in isolation is needed to 
see whether the GF diet is effective in the management of IBS. 
Many other diets have been used for the management of IBS in the community 
including; the paleo diet, specific carbohydrate diet, low amine diet and elimination 
diet, however, the evidence for the use of these diets in IBS is currently limited. 
More recently, the short-term exclusion diet that eliminates a group of short-chain 
carbohydrates, called the low FODMAP diet is showing promising results in alleviating 
symptoms in people with IBS (7, 8, 58). The role of FODMAPs in IBS will be 












Table 2.2. Summary of exclusion diets used for the management of IBS symptoms  
Diet Diet Details Possible Mechanism of Action Evidence 
Specific carbohydrate diet (SCD) Exclusion of complex carbohydrates 
and refined sugars (59). All grains, 
processed meats and dairy products 
containing lactose are also excluded 
(60, 61).  
 
 
Malabsorption of these 
carbohydrates could lead to 
bacterial dysbiosis causing 
intestinal inflammation (59). 
There are advocates for the use of the 
SCD in IBS (59), However, minimal 
evidence exists for its effect on 
functional GI symptoms without the 
presence of inflammation (62).  
 
One study compared the SCD to the 
LFD in 60 IBS patients (61). While the 
LFD showed improvement in 
symptoms, the SCD improvement was 
not significant.  
Palaeolithic diet Excludes all cereal/grains, dairy 
products and legumes (63).  
Diet made up of fruits, vegetables, 
lean meats, poultry and fish with lean 
meats and non-cereal plant-based 
foods (63). 
The human gastrointestinal tract 
has poorly adapted to evolutional 
dietary changes and therefore 
exposure of modern foods that 
were not available during 
evolution is thought to cause 
disease (64). 
There is minimal high-quality evidence 
surrounding the paleo diet in disease 
(63). 
 
There is no research to date for the use 
of the paleo diet in IBS. 
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Low amine/histamine diet Restricts all foods high in amines 
including: fish, aged cheeses, meat 
products, fermented foods, some 
vegetables, wine and beer (65).  
Foods challenged later to assess 
tolerance 
Some patients may have reduced 
activity of diamine oxidase which 
could impair histamine 
degradation resulting in excess 
histamine. This may lead to 
symptoms including diarrhoea, GI 
upset and other extra-intestinal 
symptoms (66) 
There is limited evidence for the use of 
the histamine diet in IBS.  
 
Results from a self-reported 
questionnaire in a study of 115 IBS 
patients found 58% of patients 
attributed amine-rich foods to 
symptoms (50). 
Gluten free diet Strict exclusion of all food containing 
gluten found in wheat, rye, barley and 
oats.  
The mechanism by which gluten 
may have play a role in IBS 
symptoms is still unclear. 
The evidence surrounding the GF diet 
in IBS management is conflicting and 
requires further investigation into the 
role of gluten itself in the generation of 
symptoms. 
  
Double-blinded placebo controlled 
RCTs have found symptoms to 
significantly worsen with gluten (55, 
56). However, these effects could not 
be isolated to gluten alone and may be 





Conversely, a follow up study found no 
specific effect of gluten in symptom 
induction in patients with IBS after 
FODMAP reduction (57).  
Low chemical/elimination diet Restricts common food allergens such 
as: eggs, fish, seafood, nuts, peas and 
beans; Chemicals found in foods: 
salicylates, monosodium glutamate, 
benzoates, propionates, sulphites, 
nitrates, sorbic acid, antioxidants and 
colour and certain medications and 
hygiene products that contain these 
chemicals (67, 68). 
Re-challenge after 2-4 weeks to assess 
tolerance (68) 
Proposed that these chemicals in 
food induce symptoms through 
stimulation of nerve endings in 
people with hypersensitivity (68) 
Although it is used in clinical practice, 
there are no controlled trials for the low 
chemical diet in IBS and there is 
insufficient evidence for its use in IBS. 
 
One single-blind study found 
prevalence of salicylate intolerance to 
be 0.6% in those with IBS, although 
these patients had suspected salicylate 






FODMAPs is a collective term for a group of short chain carbohydrates that are poorly 
absorbed in the small intestine and thought to trigger symptoms in people with IBS. 
These FODMAPs include; excess fructose, lactose, fructans, galacto-oligosaccharides 
(GOS), and the sugar alcohols sorbitol and mannitol (70). FODMAPs are found in 
various everyday foods and examples of foods high and low in FODMAPs are listed in 
Table 2.3. How these short chain carbohydrates are absorbed in the body is important 
for understanding their malabsorption in individuals. 
2.3.1 Individual FODMAPs 
Lactose is a two-chain sugar molecule found in dairy products such as milk and 
yoghurt. Lactose is broken down by the enzyme lactase into glucose and galactose 
where it can then be readily and actively absorbed (71). Malabsorption of lactose occurs 
due to a deficiency of the enzyme lactase (4). This deficiency can occur in some people 
with IBS and can vary greatly between ethnicities (70). Average lactose consumption in 
a healthy population in Sweden was reported to be 12 grams per day (72), and in an IBS 
population in the UK around 7 grams per day (73).  
Fructose is a monosaccharide found in many fruits, honey and high fructose corn syrup 
(4, 10). Fructose absorption occurs via two different transport pathways. Fructose can 
be efficiently absorbed through the GLUT-2 transporter. However, this relies on the 
presence of glucose with which fructose is co-transported. When fructose is in excess of 
glucose (known as excess fructose), it is poorly absorbed in the small intestine due to 
the low capacity of the transporter GLUT-5 (10). Average fructose consumption has 




Table 2.3: Foods containing FODMAPs and low FODMAP alternatives (75) 
 





Cereals: Wheat, rye and barley 
containing foods (e.g. bread, pasta, 
crackers) 
Legumes: Chickpeas, lentils, kidney 
beans, baked beans 
Nuts and seeds: pistachios, almonds, 
cashews, butter beans, soya beans,  
Vegetables: Artichokes, beetroot, 
savoy cabbage, cassava, garlic, leeks, 
onions, peas, shallots, snow peas, taro, 
canned corn 
Fruits: Watermelon, white peach, 
persimmon, custard apple, ripe banana, 
grapefruit, nectarine, plum, 
pomegranate 
Plant based dairy: oat milk, soy milk 
(from soy bean), long life coconut milk 
Vegetables: 
Alfalfa, aubergine (eggplant), 
bean sprouts, green beans, 
capsicums (red and green), 
bok choy, broccoli, brussel 
sprouts, common and red 
cabbage, carrot, celeriac, 
chilli, courgette, cucumber, 
fennel, ginger, kale, lettuce, 
leek leaves, green tops of 
spring onion, potato, Japanese 
pumpkin, radish, silver beet, 
spinach, tomato, turnip, yam 
 
Fruits: 
banana (unripe), blueberry, 
rock melon, dragon fruit, 
grapes, kiwi fruit, mandarin, 
honeydew melon, orange, 
passionfruit, paw paw, 
pineapple, raspberry, rhubarb, 
strawberry 
 
Protein/legumes:   
Eggs, plain cooked meats, 
seafood, tofu, tempeh, 
chestnuts, flax seeds/linseeds, 
macadamia, mixed nuts, 
brazil nuts, peanuts, pinenuts, 
chia seeds, poppy seeds, 
sunflower seeds, walnuts, 
canned lentils, Quorn mince,  
 
Dairy:  
Lactose free milk, almond 
milk, brie cheese, feta cheese, 
hard cheeses, soy milk (made 
from soy protein) 
 
Sweeteners: 





Dairy products: Cow, goat and sheep 
milk, cream, ice cream, custard, 





Fruits: Apples, pears, mango, 
watermelon, cherries, tinned fruit, 
boysenberry, feijoa, figs, tamarillo, 
Vegetables: Sugar snap peas, 
asparagus, Jerusalem artichokes, 
broccolini 
Sweeteners: fructose, high fructose 
corn syrup, honey 






Sweeteners in foods: Sorbitol, 
mannitol, xylitol, maltitol, isomalt,  
Vegetables: Cauliflower, mushrooms, 
snow peas, corn, kumara (sweet 
potato) 
Fruits: Avocado, apples, apricots, 
lychee, pears, nectarines, peaches, 
plums, watermelon, blackberry 
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Fructans and galactans (GOS) are types of oligosaccharides made up of fructose or 
galactose monomers (76). Common food sources include wheat, “windy” vegetables 
such as onion, garlic and asparagus, legumes and some fruits. All humans lack the 
hydrolase enzymes to break these bonds and therefore, fructans and galactans are poorly 
absorbed in all individuals (70, 77). In the UK average GOS intake was reported to be 2 
grams per day, and fructan consumption at 3.6g/d in an IBS population (73). 
Polyols including sorbitol and mannitol are sugar alcohols found in a variety of foods 
and used commonly as artificial sweeteners in many foods. Polyols do not have an 
active transport system and are only partially absorbed by passive diffusion in the small 
intestine, depending on their size and concentration (10). Polyol consumption has not 
been well studied although one IBS study in the UK found consumption of 0.6g/d (73).  
2.3.2 FODMAPs in the diet 
 
Data on average FODMAP consumption in the diet are lacking which may be due to 
limited availability of FODMAP analysis databases. One study in New Zealand found 
that the average consumption FODMAPs was 21.7 grams per day in an elderly 
population (78). In Australia the average consumption of FODMAPS from the typical 
Australian diet is approximately 23.7g (79). 
2.3.3 Role of FODMAPs in IBS 
Due to individual differences in absorptive patterns in the small intestine, not all of the 
FODMAPS described will induce symptoms in patients with IBS (80). However, these 
FODMAPs all share three common properties that can contribute to IBS symptoms; 
they are poorly absorbed in the small intestine, rapidly fermentable by colonic bacteria 
and are osmotically active (figure 2) (10). 
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 As these FODMAPs are poorly absorbed, they travel to the large intestine where they 
are fermented by colonic bacteria (81). This fermentation process produces hydrogen 
and methane gas in the bowel, causing luminal distension. This hypothesis has been 
confirmed in a study by Ong et al. (2010) that used hydrogen breath testing to show a 
low FODMAP diet significantly decreased hydrogen gas production in IBS and healthy 
people (11). Murray et al. (2013) also support this, finding an increase in hydrogen 
production and colonic gas seen on MRI scans after ingestion of fructose and fructans 
(12).  
FODMAPs are also highly osmotically active, drawing water into the small and large 
intestine, which also causes luminal distension and can alter gut transit time. This 
osmotic effect has been demonstrated in a number of studies. A study of ileostomates 
found that ingestion of FODMAPs resulted in an increase in water delivery to the colon 
by 20%, and a 22% increase in effluent collection compared to low FODMAP intake 
(13). A similar finding using magnetic resonance imaging saw a significant increase in 
small bowel water content following ingestion of fructose (12). These studies show the 
osmotic effect and poor absorption of FODMAPs and support the theory that these 
effects are associated with the IBS symptoms of abdominal distension and diarrhoea. 
The luminal distension caused by both gas production from bacterial fermentation, and 
increased luminal water content from the osmotic properties of FODMAPs, can cause 
symptoms of bloating and abdominal pain in patients with IBS who have visceral 
afferent hypersensitivity (10). The increase in water delivery to the bowel and gas 















Figure 2. Physiological effect of FODMAPS. 
FODMAPs are poorly absorbed in the small intestine, have an osmotic effect drawing water into the 
bowel and are fermented by colonic bacteria in the large bowel producing hydrogen and/or methane gas. 
The osmosis and fermentation can lead to bloating, abdominal pain and diarrhoea in IBS patients. Figure 
from Barret et al (13). 
 
Although FODMAPs are poorly absorbed to a degree in all individuals (10), studies 
have linked FODMAP ingestion with IBS symptoms. One magnetic resonance imaging 
study that found an increase in small bowel water content following ingestion of a 
poorly absorbed carbohydrate (lactulose), also found that this increase was associated 
with more severe symptoms in patients with IBS compared to healthy controls (15). 
Masuy et al. (2018) found increased gas production was also associated with increased 
symptom severity in patients with IBS but not healthy controls (16). These studies 
support the theory that FODMAPs cause luminal distension and provide evidence for 
their role in symptoms of IBS. 
Although it has been shown that FODMAPs increase luminal distension through gas 
production and liquid content and this is thought to contribute to symptoms in patients 
with IBS, luminal distension occurs in both healthy people and those with IBS. The 
reason that only patients with IBS experience these symptoms from luminal distension 
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is thought to be related to factors such as visceral hypersensitivity, disordered gut 
motility and altered gut microbiota that are absent in healthy people (10, 14).  
2.3.4 Efficacy of the low FODMAP diet 
 
The low FODMAP diet has been extensively studied since it was first introduced in the 
early 2000s and there is good evidence to support its efficacy. There have been many 
studies looking at the efficacy of the low FODMAP diet (Table 2.4). Firstly, there have 
been a few observational studies that have found significant improvement in IBS 
symptoms following the low FODMAP diet (82-85), although these are limited due to 
their retrospective, uncontrolled nature and/or lack of adequate control groups.  
Many studies assessing the low FODMAP diet have been randomised controlled trials 
(RCT). Many have compared the low FODMAP diet to other interventions including 
habitual intake, NICE guidelines, a high FODMAP diet, and gut-directed hypnotherapy. 
A few RCTs comparing the low FODMAP diet to habitual intake have found significant 
improvements in symptoms on the low FODMAP diet compared to habitual intake (73, 
79, 86). Although a limitation to the use of a habitual diet as a control is that no dietary 
intervention is given to this group, which can make it a weak comparator group.  
Many studies have assessed the Low FODMAP diet in comparison to the traditional 
IBS diet from the NICE guidelines (49-51). Two of those studies found improvement in 
symptoms however, found no significant difference between the two treatments (50). 
Although one of those studies did find a significant improvement in individual 
symptoms including pain and bloating for the low FODMAP diet indicating that it may 
have some benefits over the NICE guidelines (49). A non-randomised study also found 
an improvement in symptoms on the low FODMAP diet and NICE guidelines although 
this was significantly greater on the low FODMAP diet (51). There have been two 
systematic reviews and meta-analyses with conflicting results on whether the low 
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FODMAP diet is superior to following the NICE guidelines (7, 9). Therefore, although 
there is some conflicting evidence, it does appear that the low FODMAP diet is at least 
as effective as the NICE guidelines, if not more so in improving individual symptoms. 
Two studies have assessed the extremes of a low vs high FODMAP diet (11, 87). These 
studies found that GI symptoms were significantly increased in the high FODMAP diet 
in IBS patients compared to those in the low FODMAP group.  However, a limitation 
when comparing two extremes is that such comparisons may exaggerate the results. 
There has been one study comparing the low FODMAP diet to gut-directed 
hypnotherapy in a randomised controlled trial (43). This study found both treatments to 
be effective at improving IBS symptoms after 6 weeks with no significant differences 
between groups suggesting the low FODMAP diet and gut-directed hypnotherapy may 
have similar efficacy. 
Although these studies all support the efficacy of the low FODMAP diet, strong study 
designs can be very difficult to implement in dietary interventions and there are some 
common limitations across these studies.  
Firstly, these studies all have a small sample size (<100 people), although, the 
completion rates in these studies were mostly >80% suggesting that the low FODMAP 
diet is not overly difficult to adhere to. The two studies that had poor compliance; <50% 
were explained by the migration of people out of their region following an earthquake, 
and the other with 65% completion was due to loss to follow up (82, 84). Most of these 
studies were of short duration, however, when carrying out a long dietary intervention it 
can be extremely challenging to maintain adherence. Furthermore, a strict low 
FODMAP diet is usually only advised for 4-6 weeks before controlled reintroduction of 
FODMAP containing foods, thus the length of many of these studies reflected clinical 
practice. There have been two studies that have shown long term efficacy of the low 
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FODMAP diet with symptom improvement maintained after 6 and 15.7 months (43, 
84).  
Double-blinded randomised placebo-controlled trials are considered the highest quality 
evidence in dietary intervention studies, necessary to reduce the placebo effect which is 
known to be high in patients with IBS (6, 88). However, this study design can be 
extremely difficult to implement in dietary interventions. Providing food in a dietary 
intervention gives a level of blinding and minimises confounders. There have been two 
randomised single-blinded cross-over studies that have provided all food. In one study 
of 30 IBS participants, the low FODMAP diet was compared to the typical Australian 
diet. On the low FODMAP diet 70% of IBS participants had lower overall 
gastrointestinal symptom scores compared to the typical diet and baseline (79). The 
other study compared a low vs high FODMAP diet for 2 days each and found symptom 
severity was significantly reduced in the low FODMAP group and symptoms were 
significantly induced on the high FODMAP diet (11).  
Although providing food allows some blinding and a much more controlled study, it 
does not reflect a real-life setting. A recent placebo-controlled RCT compared the low 
FODMAP diet to a ‘Sham’ diet that was designed to have the same difficulty to follow 
as the low FODMAP diet but matched it for other dietary constituents such as fat, 
protein and carbohydrates (89). In this study patients received dietary advice by a 
Dietitian and followed similar protocol as would happen in clinical practice. This study 
found lower total symptom severity scores on the low FODMAP diet (173 ± 95) 
compared to the Sham diet (224 ± 89) (p=0.001). This high-quality evidence shows the 
benefit of the low FODMAP diet when using an adequate control and alongside other 
studies, supports the efficacy of the low FODMAP diet. Recently, three meta-analyses 
have also supported the efficacy for the low FODMAP diet (7-9). 
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Table 2.4 Summary of studies assessing the low FODMAP diet in IBS 












 79 IBS patients 
(Rome III) 
36 unguided IBS 
patients 
 43 guided IBS patients 
receiving dietary advice 
on avoiding FODMAPs. 
 













Significant reduction in abdominal pain, 
for guided IBS patients vs unguided 
(p<0.05). 
 
No significant differences in the total 
score or diarrhoea/constipation for 
guided vs unguided IBS patients  





212 IBS patients 









inulin and lactose to 
determine tolerance 
 
Advised by Dietitian 
4 weeks 10-point Likert 
scale on 
symptoms 
Overall, AR of global symptoms was 
experience in >80% of patients.  
 
Symptomatic relief experienced in 93% 
and 96% of people with fructose and 
lactose malabsorption respectively.  





90 patients with 
IBS diagnosed by 
a 
gastroenterologis
t or a colorectal 
surgeon (criteria 
not stated) 
Low FODMAP diet 
initial consult and a 6-
week follow up 
 
Advised by Dietitian 









efficacy of diet 
through email or 
post 
Significant symptom improvement in 
44% of patients for abdominal pain, 
38% for bloating, 38.5% for constipation 
and 60% for diarrhoea at follow up 
 














Avoidance of   high free 
fructose (in excess of 
glucose) (>0.5g/100g), 
fructose load (>3g in a 
serve), 
high fructan foods 
(>0.5g/serve) 
 











as score >5) 
74% of patients with IBS had a positive 
response to all abdominal symptoms 
 
Positive response was significantly 
greater in those who adhered (86%) to 
non-adherers (36%) (p<0.01) 
Randomised Controlled trials 
Staudacher et al 
(73)  
RCT 41 IBS 
participants 
(Rome III) 
LFD (n=19) vs habitual 
(n=22),  
 
Advised by Dietitian 
4 weeks GSRS Adequate relief of symptoms on LFD 
(68%) vs control (23%) (p=0.005) 
 
Reduced bloating, borborygmic and 
overall symptoms in LFD vs control 
(p<0.05) 














LFD vs typical diet 
  









Lower overall GI symptoms in LFD 
(23mm) vs control (45mm) (p<0.001) 
 
70% IBS participants had lower overall 
GI symptom scores on LFD vs typical and 
baseline 





108 IBS patients 
(Rome III) 
LFD (n=34) 
Habitual/Danish (n=37)  
Habitual + probiotic 
(n=37) 
6 weeks  IBS-SSS,  
IBS-QOL 













LFD (51) vs Sham diet 
(53) 
 
Advised by Dietitian 
4 weeks IBS-SSS 
IBS-QOL  
Total IBS-SSS lower on the LFD (173± 95) 
vs Sham (224± 89) (p=0.001) 
 
No significant difference between 
groups for AR of symptoms with 
ITT (75% LFD vs 30% Sham p=0.68), and 
for  
PP (61% vs 39% p=0.42) 
Comparison trials 









LFD vs HFD,  
 
Advised by Dietitian 
3 weeks IBS-SSS IBS-SSS significantly reduced in low 
FODMAP group p<0.001 
 
Greater proportion responded to the 
low FODMAP 72% compared to high 
21% (p<0.009). 










2 days LFD (9g/d) and 2 
days HFD (50g/d) 
 
7 day wash out period 
between diets 
 
No advice- all food 
provided 
4 days Unvalidated GI 
questionnaire 
All GI symptoms were significantly 
worsened in IBS patients on the HFD 
compared to LFD (p<0.05). 
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LFD vs NICE guidelines,  
Advised by Dietitian 
4 weeks IBS-SSS Symptom severity reduced in 50% on 
the LFD and 46% in the NICE diet, with 
no significant differences between 
groups 










NICE guidelines (n=39) 
 
Advised by Dietitian 












76% of participants on the LFD reported 
satisfaction with their symptoms 
compared to 54% in the NICE group (p = 
0.038) 




84 IBS-D patients LFD vs modified NICE 
diet, advised by 
dietitian 
4 weeks IBS Symptom 
questionnaire 
LFD resulted in a higher proportion of 
abdominal pain responders compared 
with the mNICE group (51% vs. 23%, P 
=0.008). 
 
Significant reductions in abdominal 
pain, bloating, stool consistency, 
frequency, and urgency in LFD vs NICE. 
 
No significant differences between the 
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LFD and mNICE for AR of symptoms 
(52% vs 41% p=0.31)  









Advised by dietitian 
6 weeks  
 




Symptom improvement in 72% 
participants receiving GDH, 71% on the 
LFD and 72% receiving combination, 
with no significant differences across 
groups p=0.67 
 
Improvement maintained at 6 months 
in 74% receiving GDH, 82% on the LFD 
Abbreviations: IBS, irritable bowel syndrome; FODMAP, fermentable, oligosaccharide, disaccharide, monosaccharide and polyols; FFQ, food frequency 
questionnaire; IBS-QOL, irritable bowel syndrome- quality of life; SF-NDI, short form Nepean Dyspepsia Index; IBS-SSS, irritable bowel syndrome- symptom 
severity scale; GSRS, gastrointestinal symptom rating scale; RCT, randomised controlled trial; LFD, low FODMAP diet; HFD, high FODMAP diet; AR, adequate 
relief; GI, gastrointestinal, GDH, gut-directed hypnotherapy; ITT, intention to treat; PP, per protocol 
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2.3.5 FODMAPs and IBS Symptoms 
As mentioned earlier, the mechanisms by which FODMAPs induce symptoms has been 
demonstrated (figure 2), and whilst the improvement in symptoms on the low FODMAP 
diet seen in many studies does indicate the role of FODMAPS, it is also important to 
examine the correlation between symptom onset and ingestion of FODMAPS, which 
has been investigated in few studies. (15-18) 
A randomised controlled re-challenge trial found that in patients with IBS following a 
low FODMAP diet, introduction of either fructans, fructose or a mixture of fructans and 
fructose resulted in a dose dependent induction of symptoms in 77%, 74% and 79% of 
patients respectively (90). Rumessen et al. (1988) also found that fructose, or a mixture 
of fructose and sorbitol both caused significantly increased abdominal distress in a 
group of patients with demonstrable fructose malabsorption (18). These studies support 
the theory that poorly absorbed carbohydrates (FODMAPs) induce symptoms in IBS 
patients. 
However, studies showing these findings have used a liquid formula of FODMAPs, 
rather than being assessed through whole food dietary intake of FODMAPs. Many of 
the studies assessing the low FODMAP diet (Table 2.4), did assess dietary intake (often 
by food diaries), yet did not use it to analyse the participants actual FODMAP intake 
and its relationship with symptoms. One RCT comparing the low FODMAP diet with a 
high FODMAP diet in relation to symptoms did measure FODMAP content through a 
14-point scoring system based on frequency of consumption of the five main categories: 
fructose, lactose, fructans, GOS and polyols. This study found that regardless of 
assigned diet, there was a positive correlation between FODMAP consumption and 
symptom severity (R2=0.25, p=0.002) (87). Although this study is one of the few that 
measured the correlation between FODMAP consumption and symptom severity, it did 
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not measure actual FODMAP content and was not clear on the system used to 
determine high or low FODMAP intake on its scoring scale. 
The definition of low or high FODMAP foods is unclear. Through clinical observation 
cut-off levels of food and drink items containing >0.5 g excess fructose, >3g fructose or  
>0.2g fructans are thought to increase the risk of symptoms in patients with IBS (10). A 
FODMAP content <0.5g per sitting is also considered low FODMAP (79), though this 
cut-off value has not been well studied.  
While there have been a few studies looking at the relationship between FODMAP 
intake and corresponding symptom induction, there are limited studies analysing the 
FODMAP content in diet and the relationship with symptoms. Further, there have been 
no studies to date looking at the correlation between the content of individual 
FODMAPs in the diet and acute symptoms, as it is thought that it is cumulative 
FODMAP intake within a meal that will predict the symptom induction rather than 
intake of individual FODMAPs (10). 
2.3.6 FODMAPs and Acute Symptom Onset 
Postprandial worsening of symptoms is common with over 2/3 of patients experiencing 
a clear relationship between meal and subsequent symptoms (3). The timing of 
symptoms has not been extensively studied. One study found great variation with over 
50% of patients’ symptoms worsening within 30 minutes after ingestion of a meal and 
the majority (93%) experiencing symptoms within 3 hours (3).  
There have been limited studies assessing the relationship of FODMAP intake and acute 
symptom onset with most studies assessing the cumulative effect of FODMAPs. One 
study of 29 IBS patients investigated the effects of ingestion of 40g fructans, fructose or 
glucose and found that symptoms were significantly greater after fructans compared to 
glucose and fructose (14). Peak symptom intensity was experienced 90 minutes post 
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fructose ingestion and 240 minutes after inulin. Although this study is one of the only 
studies to measure acute symptom response to ingestion of FODMAPs, it did not give 
information on the type, severity and duration of these symptoms.  
A recent study by Masuy et al. (2018) found that approximately 30 minutes after 
carbohydrate infusion, an increase in symptoms can be observed (16). Bloating, 
belching and fullness was observed in patients with IBS after carbohydrate infusion, 
however, there was no significant difference between the fructan and glucose solutions 
on these symptoms. A significant increase in flatulence and cramps was seen after 
fructan solution compared to glucose (p<0.001).  However, this study did not assess the 
effects of various fructan amounts on symptoms and did not assess the effects of other 
FODMAPs on acute symptoms. In both these studies, FODMAPs were given as a liquid 
solution and although these studies show a relationship between FODMAP intake and 
acute symptoms, it cannot be generalised to the effects of these FODMAPs in food.  
2.4 Summary and Aim 
There is substantial evidence showing the role FODMAPs play in symptom induction in 
IBS patients. However, data concerning the temporal relationship between dietary 
FODMAP intake and acute symptom onset and severity are lacking with most studies 
using liquid formulations of FODMAPs and/or only assessing one individual 
FODMAP. Furthermore, there is limited evidence surrounding the relationship between 
individual FODMAPs in the diet and acute symptoms. 
The aim of this research is to investigate the relationship between dietary FODMAP 
intake and acute gastrointestinal symptoms in adults with IBS and the effects of 





3. Objective Statement 
 
The mechanisms behind which FODMAPs induce IBS symptoms have been well studied. 
While research has shown the relationship between FODMAPs and IBS symptoms, there 
have been no studies looking at specific amounts of FODMAPs in the diet and their 
relationship with IBS symptoms. There is some evidence of acute symptom onset 
following FODMAP intake, although limited research on the relationship between dietary 
FODMAP intake and acute symptoms, and this relationship with individuals FODMAPs. 
This study will further investigate the role dietary FODMAPs play in IBS symptom 
induction to better understand what foods may be triggering acute symptoms. 
 
Research aim: The purpose of this study was to investigate the relationship between 
specific FODMAP consumption and acute gastrointestinal symptoms in adults with 
IBS. The research objectives are to: 
- Assess the consumption of FODMAPs in adult IBS participants 
- Investigate the relationship between dietary FODMAP content and acute 
gastrointestinal symptoms (onset and severity) 
- Investigate the relationship between individual FODMAPs and acute 









4.1 Study Design 
The aims of this study were: 
1) To investigate the relationship between FODMAP consumption and acute 
gastrointestinal symptoms  
2) To investigate the relationship between individual FODMAPs and acute 
gastrointestinal symptoms  
This thesis uses data of participants from the following two observational IBS studies. 
 The COMFORT study is a prospective case-control study of 600 participants 
undergoing a colonoscopy with or without IBS, living in Christchurch. The aim of this 
study is to identify the mechanisms of IBS pathogenesis. The first 52 participants with 
IBS that had satisfactorily completed and returned their three-day food and symptom 
diary by the 20th April 2018 were included in this thesis. 
 
The FAST validation study is a prospective observational pilot study consisting of 51 
IBS patients living in Christchurch and Dunedin. This aim of this study was to assess 
the validity of a time-specific food and symptom diary (FAST) completed by the 
participants. This study also investigated the consumption of food and subsequent 
gastrointestinal symptoms. Data from all 51 participants were used in this thesis. 
 
The study procedures relevant to this thesis included in both the FAST validation study 







4.2.1 FAST Validation Participants 
Potential participants were recruited via gastroenterology clinics, University campuses, 
medical centres and shopping areas throughout Dunedin and Christchurch between 
September 2016 and April 2017.  Those aged between 18 and 65 years who met the 
Rome IV diagnostic criteria for IBS were included in the FAST validation study. Those 
with significant co-morbidity or organic gastrointestinal disease were excluded.  
 
4.2.2 COMFORT Participants 
Participants were recruited in Christchurch by a clinician prior to their colonoscopy. 
Recruitment started in March 2016 and is still ongoing (10 May 2018).  Participants 
aged between 18 and 70 years with a diagnosis of IBS defined by Rome IV were 
included in the COMFORT study. Those with significant other gastrointestinal diseases, 
pregnant or unable to give informed consent were excluded. 
 
4.3 Study Procedures 
Potential participants gave signed informed consent, completed a demographic form and 
the Rome IV diagnostic questionnaire for adults, irritable bowel module. Eligible 
participants were given a 3-day food and live gastrointestinal symptom diary to 
complete on three non-consecutive days including one weekend day and were given 
detailed instructions on how to complete this, including examples. Once completed, 






4.3.1 Rome IV diagnostic questionnaire for adults, irritable bowel syndrome 
module 
All participants completed the Rome IV diagnostic questionnaire for adults, irritable 
bowel syndrome model (Appendix B). To be diagnosed with IBS and eligible for the 
studies, the participants must have met the following criteria below (with symptom 
onset at least 6 months prior to diagnosis). 
Recurrent abdominal pain, on average, at least 1 day per week in the past 3 months and 
associated with two or more of the following criteria:  
1. Related to defecation  
2. Associate with a change in frequency of stool  
3. Associated with a change in form (appearance) of stool (2). 
 
The Rome IV diagnostic criteria also categorized participants into one of the following 
IBS subtypes: IBS-C (constipation predominant), IBS-D (diarrhoea predominant), IBS-
M (mixed), IBS-U (un subtyped). All subtypes were included in this study. 
 
4.3.2 Demographic Questionnaires 
To assess eligibility, participants completed a demographic questionnaire including 
information on their sex, age and medical history (Appendix C and D). 
 
4.3.3 Food and Symptom Diary (FAST) 
The food and symptom diary (FAST), is a three-day food diary with a 24- 
hour scale to record information on gastrointestinal symptoms and bowel motions 
(Appendix E). This diary was validated against the GSRS, IBS-QOL and the PROMIS 
GI scales as part of the FAST validation study and was completed by the FAST 




The food diaries collected information on food and beverage consumption for three non-
consecutive days. This information included; the timing of meals, where they ate, who 
with, food items/drinks, estimated/weighed quantities, and cooking/preparation method. 
The diary also included a section for recipes that had been prepared and the portion of 
the recipe they had. To help ensure accurate recording, there were instructions with 
examples of how to fill out the food diaries. 
 
A 24-hour scale for gastrointestinal symptoms was also recorded alongside the food 
diaries. Symptoms of abdominal pain, abdominal bloating, abdominal fullness, 
abdominal swelling/distension were recorded. Participants were asked to record the time 
of each symptom, duration, and the severity on a scale of 1 ‘not very bad at all’ to 5 
‘very bad’. If one symptom did not occur, there was a tick box above the scale to 
indicate this. 
 
Participants also recorded the following information on their bowel motions; the time a 
bowel motions occurred on a 24-hour scale, the Bristol stool type, if there was straining 
before the bowel motion, how much urgency was experienced, if abdominal pain was 










4.4 Data Entry 
4.4.1 Demographic questionnaire data entry 
Data from the demographic questionnaire including their IBS subtype, were entered into 
a Microsoft Excel spreadsheet alongside their allocated participant ID, given to ensure 
anonymity.  
 
4.4.2 Food Diary Data Entry 
The food diaries were entered into The FODMAP Calculator, a FODMAP analysis 
software created by Monash University, Melbourne, Australia (92). This software 
provides information about the total daily intake of; glucose, fructose/excess fructose, 
lactose, fructans, GOS, sorbitol and mannitol. To get the amount of FODMAPs in each 
meal, one meal was recorded as one day on The FODMAP Calculator, as this is 
currently set up to provide only daily totals. The amounts of individual FODMAPs from 
each meal per participant were exported from The FODMAP Calculator to an excel 
spread sheet alongside the meal time. The candidate entered all 306 days of food diaries 
into this software, to limit interpersonal variation. This includes 100 three-day diaries 
and three diaries with only two days completed. 
The FODMAP calculator does not include meat and poultry on the database as these 
foods do not contain FODMAPs, so these items were not entered. However, other 
ingredients found in meat products such as onion, garlic and breadcrumbs found in meat 
patties, were recorded. For recipes containing meat, all other ingredients in the meal 
were entered in the amount recorded.  
Due to its newly developed and growing database, there were food items and beverages 
that were not available on The FODMAP Calculator. Items that were not available such 
as baked goods, alcoholic and diet beverages, pizza, seasonings and sauces, were 
entered either by creating recipes of that item within the database, or by substituting for 
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items with similar FODMAP content. The most common substitutions are listed in 
Table 4.1.  


















4.4.3 Symptom Diary Data Entry 
Symptom data from the FAST diaries were transcribed into a Microsoft Excel spread 
sheet. A compiled spreadsheet was also made for meal time and symptoms occurring 
within a 3-hour period post meal. Information of bowel motions were also recorded in 
this Microsoft Excel spreadsheet. 
 
Item not Available Substituted item 
Dressings and sauces e.g. aioli Mayonnaise and garlic as listed on ingredients 
of package (0.8% garlic). 
Other dressings were entered using recipes. 
Apple cider and other ciders 1:1 ratio of apple juice and beer, or for other 
ciders e.g. berry cider, regular beer was used. 
Baked goods e.g. slices, muffins, Frooze 
balls. 
Recipes for the item were found online and 
entered in the amount they consumed.  
Flavored ice cream Vanilla ice cream for lactose content 
Edam cheese Cheddar cheese (reduced fat) 
Tasty cheese Cheddar cheese 
Pizzas Flat bread with toppings listed in estimated 
amounts 
Cassava vegetable crisps (flavored sour 
cream and chives) 
Ingredients listed as on packet: 37% cassava  
Flavored yoghurt e.g. berry yoghurt Plain yoghurt used for lactose content 
Raspberry jam Strawberry jam 
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4.5 Statistical Analysis 
Demographic and presenting features are presented as frequencies (%). The average 
intakes of FODMAP(s) overall and by IBS subtypes are presented as means and 
standard deviations. The associations between FODMAP intake and the presence of 
symptoms were tested statistically using receiver operator characteristic (ROC) curves 
and summarized as the Area under the curve (AUC) with standard errors and statistical 
significance. Additionally, these results are presented as bar graphs showing the 
percentage of individuals with symptoms across FODMAP intake groups.  
 
The mean FODMAP intakes are presented by the presence and absence of symptoms 
and these means were compared using one-way ANOVA for participants overall.  The 
mean FODMAP intakes across different symptom severity levels were compared using 
one-way ANOVA for all participants and also by IBS subtype. Severities were grouped 
into levels of low (1-2 ‘not bad at all’-‘a little bad’), medium (3 ‘somewhat bad’), and 
high (4-5 ‘quite bad’-‘very bad’) for this analysis. 
The median severity and duration of symptoms was compared between groups defined 
by a cut-off level of 0.5g for total FODMAP intake using Mann-Whitney-U tests overall 
participants.   
Statistical significance was set at a two-tailed p <0.05 for all analyses. 
The statistical analyses were largely undertaken by the candidate, but advice and 
guidance were sought for the statistical testing using the ROC curve and non-parametric 








5.1 Sample Characteristics 
 
One hundred and three participants were studied including fifty-two participants from 
the COMFORT cohort and fifty-one participants from the FAST Validation cohort. 
Table 5.1 shows the demographic characteristics of the participants whose data were 
included in this study. The mean age of participants was 40.8 years and the majority of 
participants were female (88.3%).  The most common IBS subtype was IBS-D (46.6.%). 
There was one participant that was IBS-U and therefore was not included in analyses by 
subtypes. 
Table 5.1: Demographic characteristics of participants 
 All participants (n=103) 
Sex  
Female  91 (88.3%)  
Male  12 (11.7%) 
Age (mean(SD)) 40.8 (16.5) 
IBS- Subtype  
IBS-D  48 (46.6%) 
IBS-M  32 (31.1%) 
IBS-C  22 (21.4%) 
IBS-U 1 (1.0%) 
1All data expressed as n (%) unless stated otherwise 
2D= Diarrhoea predominant, M= mixed, C= constipation predominant, 
 U= unsubtyped. 
 
5.2 Participants average daily FODMAP(s) intake 
Table 5.2 shows the average daily intake of FODMAPs and individual FODMAPs. 
Overall the average daily intake of total FODMAPs was 18.6g. The individual 
FODMAP lactose contributed most to the total consumption of FODMAPs with 64% of 
FODMAP intake from lactose (11.9g). The polyols sorbitol and mannitol had the 
smallest contribution to overall FODMAP intake. There were no significant differences 
between average FODMAP intakes for each subtype with the exception of average GOS 
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intake, which was significantly higher in IBS-D and IBS-M participants compared to 
IBS-C (p<0.05). 
 
Table 5.2: Average daily FODMAP(s) intake  
All Subtypes IBS-D IBS-C IBS-M 
FODMAP (g)  18.63 (10.62) 19.27 (9.30) 18.27 (12.55) 17.74 (11.44) 
Excess Fructose 
(g) 
1.48 (1.78) 1.63 (2.17) 1.68 (1.77) 1.08 (0.98) 
Lactose (g) 11.89 (9.3) 12.74 (9.1) 12.01 (10.76) 10.33 (8.55) 
Fructans (g) 2.95 (2.8) 2.74 (0.98) 3.53 (5.88) 2.88 (1.13) 
GOS (g) 0.82 (0.60) 0.94 (0.60) * 0.52 (0.29) 0.85 (0.68) * 
Mannitol (g) 0.67 (1.02) 0.59 (0.85) 0.79 (1.11) 0.69 (1.20) 
Sorbitol (g) 0.74 (1.15) 0.58 (0.70) 1.14 (1.94) 0.72 (0.97) 
1* <0.05 is considered statistically significant 
2All data expressed as mean (standard deviation) 
 
 
5.3 Average FODMAP intake according to the presence of acute gastrointestinal 
symptoms 
 
There were significant differences in the FODMAP content of a meal for those that 
experienced some acute symptoms compared to those who did not (Table 5.3). 
Participants that experienced abdominal pain and bowel motions following a meal, had 
a significantly higher average intake of FODMAPs (3.98g v 3.24g, p<0.05) and fructans 
(0.77g v 0.48g, p<0.05), than those who did not experience these symptoms (p<0.05). 
For GOS intake, those experiencing abdominal fullness had a significantly higher intake 
than those who did not experience abdominal fullness (0.21g vs 0.14g, p<0.01). Lactose 
intake was significantly higher in those who passed a bowel motion in the following 
three hours post meal compared to those who did not (2.82g vs 1.96g, p=0.001). There 
were no significant differences in the average intakes of excess fructose, sorbitol and 








Table 5.3. Average meal intake of FODMAPS for those with an acute symptom 






















(g)           
symptom present 3.98* 2.94 3.28 3.43 4.27** 
symptom absent 3.24 3.43 3.41 3.38 3.12 
Excess Fructose 
intake (g)           
symptom present 0.33 0.33 0.3 0.22 0.28 
symptom absent 0.28 0.28 0.29 0.3 0.29 
Fructan intake (g)           
 symptom present 0.77* 0.49 0.54 0.51 0.76* 
 symptom absent 0.48 0.54 0.54 0.54 0.47 
GOS intake (g)           
symptom present 0.18 0.17 0.21** 0.16 0.16 
symptom absent 0.14 0.15 0.14 0.15 0.15 
Lactose intake (g)           
symptom present 2.43 1.63 1.99 2.38 2.82* 
symptom absent 2.09 2.22 2.19 2.12 1.96 
Mannitol (g)           
symptom present 0.041 0.062 0.046 0.039 0.04 
symptom absent 0.061 0.056 0.059 0.06 0.06 
Sorbitol (g)           
symptom present 0.227 0.253 0.197 0.112 0.209 
symptom absent 0.19 0.189 0.196 0.209 0.191 
1  ANOVA, *p value <0.05 
2 ANOVA, **p value <0.01 
3Data expressed as mean intake in grams 
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5.4 The relationship between increasing FODMAP intake and percentage of 
participants experiencing symptoms 
Receiver operating curves were used to test the correlation between FODMAP intake 
and the proportion of participants experiencing acute symptoms. This relationship is 
shown in Figure 5.1. 
Overall there were no significant correlations between total FODMAP intake per meal 
and acute symptom onset for any abdominal symptom. There was however, a 
significant correlation between increasing FODMAP intake per meal and the proportion 
of participants experiencing an acute bowel motion. When looking at the correlation by 
each individual FODMAP, the correlation between increasing intake and the proportion 
of people experiencing acute bowel motions was significant for fructans, GOS and 
lactose (appendix F). Analyses of these correlations for individual FODMAP using the 
ROC curves (appendix F) showed that the oligosaccharides GOS and fructans had 
significant correlations between increasing intake and the proportion of participants 
experiencing bowel motions, abdominal pain and fullness in the following three hours 
post meal displayed in Figure 5.2 and Figure 5.3. Other individual FODMAPs were also 
analyzed and showed some significant correlations for certain symptoms but were not 


















































Figure 5.1. Relationship between total FODMAP intake per meal and acute abdominal bloating (A), 














































Figure 5.2. Relationship between fructan intake per meal and acute abdominal bloating (A), abdominal 



















































Figure 5.3. Relationship between GOS intake per meal and acute abdominal bloating (A), abdominal 






5.5. Median Severity and Duration of Symptoms 
There were no significant differences between the median duration and severity of any 
acute symptom for FODMAP consumption of <0.5g FODMAPs compared to >0.5g 
(Table 5.4). For all participants, the median severity for most abdominal symptoms was 
2 ‘a little bad’ and for abdominal bloating 3 ‘somewhat bad’. The median severity of 
bowel motions was ‘a little bad’. The longest duration of symptoms was 120 minutes 
for abdominal swelling and abdominal bloating. Abdominal pain had the shortest 
duration of 60 minutes. 
 
5.6 Mean intake of FODMAPs by level of symptom severity 
The average intake of FODMAPs by level of severity reported is shown in Table 5.5. 
There was no significant difference in the average total FODMAP intake between the 
different severity levels of symptoms reported. There was a significantly higher intake 
of excess fructose in those reporting a higher severity of abdominal pain compared 
those reporting a lower severity (p<0.01). There was also a significantly higher intake of 
excess fructose for those who reported medium severity of abdominal swelling 
compared to low severity (p<0.037). For lactose, there was a significantly higher 
average intake of lactose in the low severity group for abdominal fullness and 
abdominal swelling compared to those in highest severity group (p<0.05). Those 
reporting medium severity of abdominal swelling had significantly higher average 
intake of fructans compared to the low and high severity groups. The analysis was also 
done by subtype and for IBS-D there were significant associations between intake of 
sorbitol and severity of gastrointestinal symptoms, and for IBS-M, associations between 






Table 5.4. Median severity and duration of symptoms experienced for meal intake 























































Severity 3 (2,3) 3 (2,3) 3 (2,3) 




Severity 2 (2,3) 2 (2,3) 2 (2,3) 




Severity 2 (2,3) 3 (2,3) 2 (2,3) 




Severity 2 (2,3) 3 (2,3) 2 (2,3) 




Severity (minutes) 2 (1,3) 2 (1,2) 2 (1,2) 
1All data expressed as median (25th percentile, 75th percentile) 
2Severity; 1 'not bad at all', 2 'a little bad', 3 'somewhat bad', 4 'quite 
bad', 5 'very bad'. 
































Low  3.69 0.51 0.14 2.6 0.03 0.2 0.2 
Med 4.7 1.32 0.19 2.52 0.03 0.24 0.4 
High  3.42 0.49 0.24 1.57 0.09 0.3 0.73*L 
Abdominal 
Bloating 
Low  3.76 0.49 0.14 2.85 0.02 0.11 0.15 
Med  3.47 0.6 0.16 2.27 0.11 0.12 0.27 




Low  3.71 0.54 0.23 2.40*H 0.04 0.18 0.32 
Med 3.01 0.54 0.16 1.72 0.05 0.23 0.31 
High  1.99 0.56 0.19 0.73 0.05 0.22 0.23 
Abdominal 
Swelling 
Low  2.94 0.44 0.14 2.11*H 0.05 0.07 0.13 
Med  3.72 0.64*L, 
H 
0.17 1.78 0.07 0.49 0.56*L 
High  1.94 0.37 0.22 0.43 0.07 0.34 0.49 
Bowel 
Motions 
Low  4.64 0.82 0.15 3.09 0.04 0.24 0.29 
Med 3.19 0.58 0.15 2.04 0.02 0.12 0.28 
High 2.08 0.46 0.32 1.06 0.13 0.01 0.11 
1 Data expressed at mean intake in grams 
2Low severity; 1-2 'not bad at all'-'a little bad', medium severity; 3 'somewhat bad', 
high severity; 4-5 quite bad'-'very bad'. 
3 ANOVA, *p value <0.05 considered statistically significant 
4*H; result significant compared to high severity group, *L; result significant 




The present study is the first to investigate the relationship between specific dietary 
FODMAP content and acute gastrointestinal symptoms in IBS patients. A significant 
positive correlation was found between increasing total FODMAP intake and the 
percentage of IBS patients experiencing acute bowel motions but was not significant for 
any abdominal symptoms. GOS and fructans did show significant positive correlations 
between intake and the percentage experiencing acute symptoms. No significant 
associations were observed between the total FODMAP intake at a meal and the 
severity of acute symptoms. However, excess fructose was significantly higher in those 
with a high severity of abdominal pain and swelling and there was a negative 
association between lactose consumption and severity of abdominal swelling and 
fullness. 
 
The mean daily intake of FODMAPs in this study was 18.6g. This amount is less than 
what was reported from a typical Australian diet of 23.7g (79), and a NZ elderly 
population of 21.7g (78). The highest individual FODMAP contributor to the overall 
FODMAP intake was lactose, similar to other studies assessing habitual intake (78, 79). 
The average daily intake of lactose (11g) in the present study was higher than reported 
in an IBS population of 7g (73), but similar to a healthy population in Sweden of 12g 
(72), suggesting that patients may not be excluding lactose as IBS patients often exclude 
foods to self-manage their symptoms (93).  
 
There was a significantly higher average FODMAP and fructan intake in those 
reporting acute abdominal pain and bowel motions compared to those that did not have 
these symptoms. When acute bowel motions were present, there was a higher lactose 
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intake. In the presence of acute abdominal fullness there was a significantly higher GOS 
intake. 
These findings support the known role FODMAPs play in IBS symptom induction (11, 
14, 18, 90). FODMAPs are poorly absorbed in the small bowel, fermented by colonic 
bacteria and have osmotic properties which draw water into the lumen, all causing 
luminal distension. This has been linked to IBS symptoms of abdominal pain, bloating 
and diarrhoea in IBS patients with visceral hypersensitivity, as seen in this study (10). 
However, it is important to note that for bowel motions, the present study did not 
consider the Bristol stool type, just the presence of a bowel motion and so this result 
cannot be directly linked to abnormal bowel motions. Future research in these cohorts 
will look at the correlation between FODMAP intake and acute bowel motions by 
Bristol stool type to be able to show the correlation with abnormal bowel motions.   
There was no significant difference in the average intakes of excess fructose, mannitol 
and sorbitol between the presence or absence of symptoms. A reason behind this may be 
that for these individual FODMAPs, the average intake for both those experiencing and 
not experiencing symptoms was <0.5g which is considered low FODMAP content in 
the literature (79).  
 
The average meal intake of FODMAPs in the presence of abdominal pain symptom was 
3.98g, although there is not a clear cut-off level for low or high FODMAP content 
worldwide, this is above the cut-off level <0.5g of FODMAPs per sitting suggested in 
the literature that above this level, there is an increased risk of symptom induction (77). 
For fructan intake, >0.2g of fructans per sitting is thought to increase the risk of 
symptom induction (77). In the present study the average meal intake of fructans with 
the presence of acute abdominal pain and bowel motions was above this at 0.76g and 




No correlation was found between overall FODMAP intake per meal and the percentage 
of IBS participants experiencing acute symptoms, except for bowel motions. The 
present finding is contrary to one study that showed a dose dependent symptom 
induction after introduction of fructose, fructans, or a mixture of both, in 70, 77 and 
79% of participants respectively (90). A possible reason behind the differing result is in 
that study, liquid doses of FODMAPS were given throughout the day and even the low 
dose of 7g/d fructans and 14g/d fructose was much higher than the average daily intakes 
in the present study (excess fructose 1.48g/d and fructans 2.95g/d), so doses used in that 
study were likely to surpass more individuals’ thresholds. At a lower range of intake as 
in the present study, individual thresholds will cause greater individual variation in the 
response to FODMAP intake resulting in a less significant effect. 
 These results suggest that there may not be a single cut-off level of FODMAP intake to 
prevent acute symptoms, highlighting the importance of individualized IBS 
management, especially when determining individual thresholds to FODMAPs. 
Individualized dietary advice given by a dietitian seems to be pivotal for the success in 
improving IBS symptoms as shown in many trials assessing the low FODMAP diet 
(Table 2.4).  
A significant correlation was found between overall FODMAP intake per meal and 
onset of acute bowel motions. This finding supports research of the role FODMAPs 
have in inducing diarrhoea through osmotic properties (10). This is one of the first 
studies to look at the correlation between increasing FODMAP intake and acute bowel 
motions, however, as mentioned earlier, Bristol stool type was not considered in this 




The correlations for individual FODMAPs, show that GOS and fructan intake was 
significantly correlated with the onset of abdominal pain, abdominal fullness and bowel 
motions. It is thought that the total FODMAP amount at any meal is what contributes to 
symptom induction rather than intake of individual FODMAPs (10). However, the 
present study is the first to assess the relationship between individual FODMAPs in the 
diet and symptom onset and suggests that oligosaccharides do play a role in acute 
symptom induction and it may be that IBS patients in general are more sensitive to this 
FODMAP. 
 
No significant correlation was found between average overall FODMAP intake by level 
of severity reported, or between the median duration and severity of symptoms using 
the cut-off value of 0.5g FODMAP. These results are contrary to a previous study that 
found a positive correlation between the level of FODMAP consumption and symptom 
severity (87). However, this study based FODMAP intake on the frequency of 
consumption whereas the present study had the advantage of obtaining specific 
FODMAP content which may explain the differing results. The median severity overall 
for most symptoms was ‘a little bad’ and for abdominal bloating ‘somewhat bad’. This 
may explain why there were no associations for FODMAP intake and severity as most 
severities reported were mild. Future research should assess a population with a more 
even distribution of severities including more patients with severe symptoms, to better 
assess the relationship between FODMAP intake and severity of symptoms. 
 
For individual FODMAPs, a higher average intake of lactose was seen in those 
reporting low severity for abdominal swelling and fullness compared to those reporting 
higher severities. These findings are similar to a previous study assessing lactose intakes 
in middle-aged IBS participants, that found a higher intake of lactose was associated 
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with a lower pain score (94). As mentioned previously, lactose intolerance is relatively 
common in people with IBS (95, 96). The reason behind the negative association could 
be that lactose reduces symptom severity, however, with the known role FODMAPs 
play in symptom induction and the beneficial effect seen from removing lactose from 
the diet in some IBS patients, this reasoning is unlikely (10, 96). Lactose is an easy 
FODMAP for patients to identify as a trigger as it is found in one food group and has 
often been reported as a common trigger for IBS symptoms (45, 97). Therefore, a more 
likely explanation is that participants with lactose intolerance who have experienced 
severe symptoms may have already removed lactose-containing foods from their diet. 
A significant association was found between a higher average intake of excess fructose 
and a high severity of abdominal swelling. This result differs from a previous study that 
found no association between fructose intake and pain score (78), however, that study 
did not measure fructose in excess of glucose, which is when fructose behaves as a 
FODMAP and may explain the difference in results. Other studies have also supported 
the present finding of severe acute symptoms after fructose using liquid formulations, 
although the present study is the first to show the effects of dietary free fructose on 
acute symptoms (18, 85, 90). The present study focused on outcomes for all IBS 
participants, however, when analyzing by subtypes there were significant associations 
for IBS-M between severity and mannitol, and for IBS-D and sorbitol. Future research 
should investigate the relationship between the effect of individual FODMAPs on acute 
symptoms for each subtype. 
 Overall there was no consistent relationship between intake of FODMAPs and the 
severity of acute symptoms. One reason for the lack of significance between FODMAP 
intake and the severity of symptoms could be due to other dietary components that may 
play a role in symptom severity that were not accounted for in this study. In a study 
using a self-reported questionnaire, 70% of IBS patients reported developing symptoms 
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after consuming poorly absorbed carbohydrates, but found that those reporting higher 
severities attributed their symptoms to more food items than those reporting low 
severities (45).  So, it may be that those experiencing severe symptoms, react to more 
foods items. Also, participants may have been taking medication or supplements to 
alleviate symptoms which were not addressed in this study and could have influenced 
the results.  
Another reason may be that while FODMAP intake may be associated with the 
symptom induction, the severity and duration of symptoms experienced by an 
individual may be affected by a multitude of other factors rather than food intake. The 
perception of pain is influenced by many factors including cognition, emotions, genetics 
and physical factors and therefore the experience is individualized and highly subjective 
(98, 99). Cognitive and emotive factors such as anxiety and depression which are 
common in IBS, are known to affect the processing and intensity of pain experienced by 
an individual and stress has been associated with worsening IBS symptoms (4, 98, 100). 
Recently, the level of visceral hypersensitivity has also been shown to be associated 
with symptom severity (101). Therefore, it is possible these factors rather than 
FODMAP intake alone, influence the severity of symptoms experienced and future 
research could investigate this relationship alongside dietary intake.  
 
As the FODMAP analysis software is a new and growing database, there were many 
food items that were missing, although every effort was made to make appropriate 
substitutions. The candidate entered all food diary data eliminating inter-variation and 
ensuring consistency in substitutions made. The analysis software used did not analyze 
other dietary components, so these were not accounted for in this study. Future research 
should analyze FODMAP content alongside other dietary components to address 
potential confounders. To better understand the role FODMAPs play in acute symptom 
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onset, the relationship between FODMAP intake and timing to symptom onset should 
also be investigated. Further research should also assess Bristol stool type to get a 
clearer understanding of the role FODMAPs play in acute bowel motions. 
 
In conclusion, a higher meal intake of FODMAPs has been shown to play a role in acute 
symptom onset however the type and amount of FODMAP causing these symptoms 
seems to be somewhat individualized. Oligosaccharides have been shown to play a role 
in acute symptom onset suggesting that IBS patients may be more sensitive to this 
FODMAP. Excess fructose may have an impact of the severity of some acute symptoms 
in IBS patients, however, symptom severity may be influenced by a multitude of other 
factors rather than dietary FODMAP content alone. These results show some 
associations between FODMAP intake and acute symptoms and imply that thresholds 
for intake and perception of pain is individualized. This study shows the complexity of 
the role FODMAPs play in acute symptoms and highlights the need for individualized 











7. Application to Dietetic Practice 
IBS is not a curable condition, and with the pivotal role diet plays in the genesis of IBS 
symptoms, dietary management is an established way to help manage IBS symptoms. 
This makes dietitians the expert health professional for the management of IBS.  
 
This study found that oligosaccharide consumption was associated with acute IBS 
symptoms, showing that the IBS population may be more sensitive to this FODMAP 
more so than other individual FODMAPs. This finding will be useful for dietitians as it 
allows a better understanding of the foods that are more likely to cause acute symptoms 
and to look out for these during dietary assessment. 
 
In those with IBS, FODMAP intake is shown to be related to some acute symptoms, 
although the level of FODMAPs causing these symptoms and the severity of symptoms 
experienced is likely to differ between individuals. These results highlight the 
importance of dietitians in the management of IBS to deliver individualized dietary 
advice to determine an individual’s threshold to different FODMAPs.  
The results from this study allow dietitians to gain a further understanding of the role 
FODMAPs and individual FODMAPs play in acute IBS symptoms. Dietitians are 
essential for the management of IBS symptoms and these results reinforce the 
importance of tailoring dietary advice and assessment for each individual especially for 
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F2 What is your date of birth? (Please write down) 
 
  day    month     year 
 
F3 What is your Height (in cm) and Weight (in kg)? Height:                                                          
Weight: 
 
F4 What is your highest level of educational 
training, or equivalent? 
Postgraduate qualifications 
 
University graduate (3 years or more) 
 
Completed Polytechnic or equivalent 
certificate/associate diploma, trades 
apprenticeship, or 2 years at 
university 
 
NCEA Level 3 / University Bursary 
 
Completed Year 11 (Fifth Form/School 
Certificate/NCEA level 1) 
 
Some years at High School 
 
Primary School only 
 
 












F7 What is the date that you filled in this survey? (Please write down) 
 






Now we would like to finish off by asking you some general questions about yourself. 
 




Appendix D: Demographic form for FAST Validation Study (Size and formatting 




Welcome to our questionnaire about the short term food and symptom diary for patients with 
irritable bowel syndrome. In this survey you will be asked questions about your symptoms. The 
questionnaire will take approximately 10 minutes to complete.  
  
Your participation in this study is completely voluntary. There are no foreseeable risks 
associated with this project. However, if you feel uncomfortable answering any questions, you 
can withdraw from the survey at any point. It is very important for us to learn your opinions.  
  
Your survey responses will be coded and will remain confidential. If you have questions at any 
time about the survey or the procedures, you may contact either Morag Wright-McNaughton 
or Paula Skidmore (Dunedin) on 034797958 or Sebastiaan ten Bokkel Huinink or Richard 
Gearry (Christchurch)  on 03 3641567.  
Another option to contact us is to send an email to foodandsymptomdiary@outlook.co.nz.  
  




Please state your email address. This is required to send you the results of the project. Please 








Q1. Date of birth:  
 ___________________  
  
  
Q2. Sex:  
☐ Male  
☐ Female  
  
  
Q3. Are you descended from a Māori (that is, did you have a Māori birth parent, grandparent 
or  great-grandparent, etc.)?  
  ☐ Yes  
  ☐ No  





Q4. Which ethnic group do you belong to? (Please tick the box or boxes which apply to you)  
  ☐ New Zealand European  
  ☐ Māori  
  ☐ Samoan  
  ☐ Cook Island Māori  
  ☐ Tongan  
  ☐ Niuean  
  ☐ Chinese  
  ☐ Indian  
  ☐ Other, such as Dutch, Japanese, Tokelauan. Please specify:  __________  
  
  
Q5. Please indicate if you have any of the following 
conditions  (Please tick the box or boxes which apply to 
you):  
  ☐ High blood pressure  
  ☐ Low blood pressure  
  ☐ Heart problems  
  ☐ Stroke  
  ☐ Breathing problems  
  ☐ Cancer or tumour  
  ☐ Asthma  
  ☐ Migraines/headaches  
  ☐ Diabetes Type 1  
  ☐ Diabetes Type 2 
              ☐ Epilepsy   
              ☐ Arthritis  
  ☐ Kidney/bladder disorders  
  ☐ Hernia  
  ☐ Allergies/asthma  
  ☐ Blood disorder/diseases e.g. hepatitis   
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  ☐ Chronic condition e.g. lupus, arthritis  
  ☐ Other (please specify): __________  
  
  
Q6. Have you been diagnosed with any gastrointestinal disorder other than irritable bowel 
syndrome?   
(such as coeliac disease, Crohn’s disease, ulcerative colitis, bowel resection, diverticulosis)  
  ☐ Yes  





Q7. Please name the gastrointestinal disorder(s) you have been diagnosed with.   
  ☐ Crohn's Disease  
  ☐ Ulcerative Colitis  
  ☐ Coeliac Disease  
  ☐ Colorectal Cancer  
  ☐ Bowel Resection  
  ☐ Diverticulosis (Diverticular Disease)  
  ☐ Other (please specify): __________  
  
  








Q9. Are you currently taking laxatives?   
  ☐ Yes  
  ☐ No  
  
  
Q10. How often do you take laxatives?  
  ☐ Daily  
  ☐ Weekly  
  ☐ Monthly  
78 
 
  ☐ Less than monthly  
  
Q11. Do you smoke?  
  ☐ Yes  
  ☐ No, I never did  
  ☐ No, but I used to  
  
  
Q12. Do you drink any alcohol? (if yes please select from frequency options below. Please note 
that one standard drink equals one unit)  
  ☐ No  
  ☐ Yes, less than 5 units per week  
  ☐ Yes, between 5 and 14 units per week  
  ☐ Yes, between 14 and 21 units per week  
  ☐ Yes, more than 21 units per week  
Q13. In the last three months, how often did you have pain anywhere in your abdomen?  
  ☐ Never (Please skip to Q18)  
  ☐ Less than one day a month  
  ☐ One day a month  
  ☐ Two to three days a month  
  ☐ Once a week  
  ☐ Two to three days a week  
  ☐ Most days  
  ☐ Every day  
  ☐ Multiple times per day or all the time  
  
Q14. How often did this pain in your abdomen happen close in time to a bowel 
movement – just before, during, or soon after? (Percent of times with pain)  
  ☐ 0% Never  
  ☐ 10% 
  ☐ 20%  
  ☐ 30%  
  ☐ 40%  
  ☐ 50%  
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  ☐ 60%  
  ☐ 70%  
  ☐ 80%  
  ☐ 90%  
  ☐ 100% Always  
  
Q15. How often did your stools become either softer than usual or harder than usual 
when you had this pain? (Percent of times with pain)  
  ☐ 0% Never  
  ☐ 10% 
  ☐ 20%  
  ☐ 30%  
  ☐ 40%  
  ☐ 50%  
  ☐ 60%  
  ☐ 70%  
  ☐ 80%  
  ☐ 90%  




Q16. How often did your stools become either more frequent than usual or less frequent 
than usual when you had this pain? (Percent of times with pain)  
  ☐ 0% Never  
  ☐ 10% 
  ☐ 20%  
  ☐ 30%  
  ☐ 40%  
  ☐ 50%  
  ☐ 60%  
  ☐ 70%  
  ☐ 80%  
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  ☐ 90%  
  ☐ 100% Always  
  
Q17. Has it been 6 months or longer since you started having this pain?  
  ☐ No  
  ☐ Yes   
  
Bowel movements of Type 1 or 2 and also of Type 6 or 7 in the picture above can be 
considered to be abnormal. Type 1 or 2 means you are constipated, and Type 6 or 7 
means you have diarrhea.   
 
  
Q18. In the last 3 months, when you had abnormal stools, what were they usually like?   
☐ Usually constipation (like Type 1 or 2 in the picture)  
☐ Usually diarrhea (like Type 6 or 7)  
☐ Both diarrhea and constipation - that is, more than 1/4 of all the 
abnormal bowel           movements were constipation and more than 1⁄4 
were diarrhea ☐ Not applicable, because I never or rarely had abnormal 









































































































Appendix F: ROC curve test results for the relationship between increasing FODMAP 
intakes and the proportion of patients experiencing acute symptoms 
 
  
FODMAP Lactose Fructan Excess 
fructose 
Sorbitol Mannitol GOS 
Bowel 
motion 
0.00 0.00 0.00 0.58 0.61 0.22 0.00 
Abdominal 
Pain 
0.82 0.90 0.05 0.95 0.38 0.11 0.03 
Abdominal 
Swelling 
0.17 0.08 0.99 0.91 0.17 0.17 0.21 
Abdominal 
Bloating 
0.48 0.55 0.49 0.99 0.04 0.08 0.19 
Abdominal 
Fullness 
0.41 0.78 0.01 0.58 0.85 0.17 0.00 































Appendix G: Mean intake of FODMAP by level of severity for IBS subtypes 
 
IBS-D 
   1 Low severity; 1-2 'not bad at all'-'a little bad', medium severity; 3 'somewhat bad', high 
severity; 4-5 quite bad'-'very bad'. 
2*p value <0.05 considered statistically significant 
3*H; result significant compared to high severity group, *M; result significant compared to 
























   1 Low severity; 1-2 'not bad at all'-'a little bad', medium severity; 3 'somewhat bad', high 
severity; 4-5 quite bad'-'very bad'. 
2*p value <0.05 considered statistically significant 
3*H; result significant compared to high severity group, *M; result significant compared to 





























 1 Low severity; 1-2 'not bad at all'-'a little bad', medium severity; 3 'somewhat bad', high 
severity; 4-5 quite bad'-'very bad'. 
2*p value <0.05 considered statistically significant 
3*H; result significant compared to high severity group, *M; result significant compared to 
medium severity group *L; result significant compared to low severity group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
